JP2001504813A - 代用血小板、及びそれらの製造に適した抱合法 - Google Patents
代用血小板、及びそれらの製造に適した抱合法Info
- Publication number
- JP2001504813A JP2001504813A JP51910098A JP51910098A JP2001504813A JP 2001504813 A JP2001504813 A JP 2001504813A JP 51910098 A JP51910098 A JP 51910098A JP 51910098 A JP51910098 A JP 51910098A JP 2001504813 A JP2001504813 A JP 2001504813A
- Authority
- JP
- Japan
- Prior art keywords
- fibrinogen
- product
- albumin
- protein
- spacer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. RGD配列を含む本質的に性能が低下していない活性のある蛋白質が結 合された不溶性のキャリアを含んでなる、薬学的に許容される生成物。 2. 結合が、例えば吸着による非化学的なものである、請求項1に記載の生 成物。 3. 結合が、界面活性剤不在下での、化学的なリンカーを介しての共有結合 性のものである、請求項1に記載の生成物。 4. 結合が、少なくとも10nmの長さの化学的なリンカーを介しての共有 結合性のものである、請求項1に記載の生成物。 5. キャリアが架橋蛋白質微粒子を含んでなるものである、先行する請求項 のいずれか一項に記載の生成物。 6. 微粒子の蛋白質がアルブミンである、請求項5に記載の生成物。 7. RGD蛋白質がフィブリノーゲンである、先行する請求項のいずれか一 項に記載の生成物。 8. 活性のあるフィブリノーゲンを0.01〜2.5重量%と、不活性なフ ィブリノーゲンを50%以下含んでなる、請求項7に記載の生成物。 9. 式X−S−Y−Z(X−SHは遊離チオール基をもつキャリア成分であ り、Yはスペーサーであり、Zは有効成分である)の共有結合抱合体の製造法で あって、 有効成分を、式Y1−Y−Y2(Y1は遊離チオール基と選択的に反応する 基であり、Y2は有効成分と反応するがチオール基とは反応しない基である)を もつ二官能価の試剤と反応させる工程、及び 得られたY1−Y−Zをキャリア成分と反応させる工程 からなる方法。 10. Y1がIである、請求項9に記載の方法。 11. Y2がCOOHである、請求項9、もしくは請求項10に記載の方法 。 12. 二官能価の試剤が、スペーサー成分とオプションとして活性化させた ヨード酢酸との反応により得られるものである、請求項10に記載の方法。 13. スペーサーが脂肪酸もしくはペプチド鎖を含んでいる、請求項9〜1 2のいずれか一項に記載の方法。 14. 有効成分がNH2基を有している、請求項9〜13のいずれか一項に 記載の方法。 15. スペーサーの長さが10〜600nmである、請求項9〜14のいず れか一項に記載の方法。 16. キャリア成分が微粒子の形にある、請求項9〜15のいずれか一項に 記載の方法。 17. 有効成分がRGDS配列を含む蛋白質である、請求項9〜15のいず れか一項に記載の方法。 18. RGD蛋白質がフィブリノーゲンである、請求項17に記載の方法。 19. キャリアがアルブミンである、請求項9〜18のいずれか一項に記載 の方法。 20. キャリアがヒト血清アルブミンである、請求項19に記載の方法。 21. アルブミンのチオール基を介して、少なくとも50nmの長さのスペ ーサーによって有効成分に抱合されているアルブミン。 22. 請求項18、もしくは請求項20に記載の方法により得られる、請求 項21に記載のアルブミン。 23. 微粒子の形の請求項21、もしくは請求項22に記載のアルブミン。 24. 有効成分がフィブリノーゲンである、代用血小板として用いる為の請 求項20〜22のいずれか一項に記載のアルブミン。 25. フィブリノーゲンが請求項8で定義したものである、詰求項24に記 載のアルブミン。 26. メトトレキサート、ドキソルビシン、シスプラチン、もしくは5−フ ルオロ−2’−デオキシユリジンのような結合された細胞毒性剤を付加的に含む 、請求項1〜8、及び21〜25のいずれか一項に記載の生成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9621886.2A GB9621886D0 (en) | 1996-10-21 | 1996-10-21 | Microparticles and their therapeutic use |
GB9621886.2 | 1996-10-21 | ||
GBGB9702652.0A GB9702652D0 (en) | 1997-02-10 | 1997-02-10 | Conjugates and their preparation |
GB9702652.0 | 1997-02-10 | ||
PCT/GB1997/002877 WO1998017319A2 (en) | 1996-10-21 | 1997-10-17 | Platelet substitutes and conjugation methods suitable for their preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001504813A true JP2001504813A (ja) | 2001-04-10 |
JP2001504813A5 JP2001504813A5 (ja) | 2005-06-16 |
Family
ID=26310263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51910098A Pending JP2001504813A (ja) | 1996-10-21 | 1997-10-17 | 代用血小板、及びそれらの製造に適した抱合法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US5977313A (ja) |
EP (1) | EP1028752B1 (ja) |
JP (1) | JP2001504813A (ja) |
AR (1) | AR008680A1 (ja) |
AT (1) | ATE284714T1 (ja) |
AU (1) | AU718956B2 (ja) |
CA (1) | CA2269335C (ja) |
DE (1) | DE69731985T2 (ja) |
ES (1) | ES2232862T3 (ja) |
WO (1) | WO1998017319A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005504745A (ja) * | 2001-07-20 | 2005-02-17 | シエーリング アクチエンゲゼルシヤフト | 大環状金属錯体及び生体分子との結合体の製造のためのその使用 |
JP2011520913A (ja) * | 2008-05-16 | 2011-07-21 | バイエル・ヘルスケア・エルエルシー | 標的化凝固因子およびそれを使用する方法 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391343B1 (en) | 1991-01-15 | 2002-05-21 | Hemosphere, Inc. | Fibrinogen-coated particles for therapeutic use |
JP2002503254A (ja) | 1997-06-05 | 2002-01-29 | ヘモスフィア,インコーポレイテッド | フィブリノゲンをコーティングしたミクロスフィア |
GB9724143D0 (en) * | 1997-11-14 | 1998-01-14 | Andaris Ltd | Pharmaceutical conjugate |
EP1056484A1 (en) * | 1998-02-20 | 2000-12-06 | Quadrant Healthcare (UK) Limited | Products comprising fibrinogen for use in therapy |
GB9825105D0 (en) * | 1998-11-16 | 1999-01-13 | Andaris Ltd | Pharamaceutical conjugates |
GB9827813D0 (en) * | 1998-12-17 | 1999-02-10 | Andaris Ltd | Pharmaceutical conjugates |
DE19926475A1 (de) * | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Träger-Pharmaka-Konjugate |
US20040126900A1 (en) * | 2001-04-13 | 2004-07-01 | Barry Stephen E | High affinity peptide- containing nanoparticles |
US7306925B2 (en) | 2001-11-09 | 2007-12-11 | Vanderbilt University | Phage antibodies to radiation-inducible neoantigens |
WO2003028640A2 (en) * | 2001-10-03 | 2003-04-10 | Vanderbilt University | In vivo panning for ligands to radiation-induced molecules |
US7906102B2 (en) | 2001-10-03 | 2011-03-15 | Vanderbilt University | Ligands to radiation-induced molecules |
GB0323378D0 (en) * | 2003-10-07 | 2003-11-05 | Univ Leicester | Therapeutic agent |
GB0516091D0 (en) * | 2005-08-04 | 2005-09-14 | Haemostatix Ltd | Therapeutic agent |
US20080015145A1 (en) * | 2006-07-11 | 2008-01-17 | Maria Gyongyossy-Issa | Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions |
GB0623607D0 (en) | 2006-11-27 | 2007-01-03 | Haemostatix Ltd | Tissue adhesive |
ES2593584T3 (es) | 2009-05-28 | 2016-12-09 | Profibrix Bv | Sellante de fibrina en polvo seco |
GB201101740D0 (en) * | 2011-02-01 | 2011-03-16 | Haemostatix Ltd | Therapeutic agents with improved fibrinogen binding |
WO2013019730A1 (en) | 2011-07-29 | 2013-02-07 | The Washington University | Antibodies to tip-1 and grp78 |
GB201201751D0 (en) | 2012-02-01 | 2012-03-14 | Haemostatix Ltd | Haemostatic wound dressing |
US20130202675A1 (en) | 2012-02-03 | 2013-08-08 | Dynasil Biomedical Corporation | Systems and methods for the fabrication of tissue patches |
GB201204868D0 (en) | 2012-03-20 | 2012-05-02 | San Raffaele Centro Fond | Peptides |
EP3172222A4 (en) | 2014-07-24 | 2018-03-21 | Washington University | Compositions targeting radiation-induced molecules and methods of use thereof |
US9540548B1 (en) | 2015-08-07 | 2017-01-10 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
WO2017027378A1 (en) | 2015-08-07 | 2017-02-16 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
US9833538B2 (en) | 2015-08-07 | 2017-12-05 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
CN107686507B (zh) * | 2016-08-05 | 2021-02-12 | 首都医科大学 | Rgds-阿霉素,其合成,活性和应用 |
CN107686508B (zh) * | 2016-08-05 | 2021-02-12 | 首都医科大学 | 阿霉素-rgds,其合成,活性和应用 |
US11352436B2 (en) | 2017-02-10 | 2022-06-07 | Washington University | Antibodies to TIP1 and methods of use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039128A1 (en) * | 1995-06-06 | 1996-12-12 | Hemosphere, Inc. | Protein particles for therapeutic and diagnostic use |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8334499D0 (en) * | 1983-12-24 | 1984-02-01 | Beecham Group Plc | Derivatives |
GB8400653D0 (en) * | 1984-01-11 | 1984-02-15 | Beecham Group Plc | Conjugates |
US4661471A (en) * | 1984-04-10 | 1987-04-28 | New England Deaconess Hospital | Method of inhibiting and inducing human platelet aggregation |
US4666884A (en) * | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
US5069936A (en) * | 1987-06-25 | 1991-12-03 | Yen Richard C K | Manufacturing protein microspheres |
AU3149289A (en) * | 1988-03-18 | 1989-09-21 | Rockefeller University, The | Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor |
JPH04504248A (ja) * | 1988-09-30 | 1992-07-30 | ネオロクス コーポレーション | シッフ塩基で結合した、ターゲティング物質―診断/治療薬複合体 |
DK0494417T3 (da) * | 1991-01-10 | 1996-05-13 | Basf Corp | Fremgangsmåde til tværbinding af gelatine og til inkorporering af et materiale deri |
US5616311A (en) * | 1991-01-15 | 1997-04-01 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
US5725804A (en) * | 1991-01-15 | 1998-03-10 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
ATE147976T1 (de) * | 1991-01-15 | 1997-02-15 | Hemosphere Inc | Protein nanomatrizen und verfahren zur herstellung |
WO1992013547A1 (en) * | 1991-02-07 | 1992-08-20 | Alexander Mellon Eaton | Drug delivery composition and method of using the same |
AU1461592A (en) * | 1991-02-07 | 1992-09-07 | Fibratek, Inc. | Fibrinogen based adhesive |
GB9107628D0 (en) * | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
EP0673384A4 (en) * | 1992-12-10 | 1996-10-09 | Univ Minnesota | POLYPEPTIDES USEFUL IN TREATING INFLAMMABLE DISEASES. |
GB9423419D0 (en) * | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
CN1175208A (zh) * | 1994-12-16 | 1998-03-04 | 安达里斯有限公司 | 交联的微粒及其作为治疗载体的用途 |
EP0727225A3 (en) * | 1995-02-14 | 1997-01-15 | Sonus Pharma Inc | Compositions and methods for directed ultrasonic imaging |
-
1997
- 1997-10-17 AU AU47135/97A patent/AU718956B2/en not_active Ceased
- 1997-10-17 EP EP97909451A patent/EP1028752B1/en not_active Expired - Lifetime
- 1997-10-17 WO PCT/GB1997/002877 patent/WO1998017319A2/en active IP Right Grant
- 1997-10-17 JP JP51910098A patent/JP2001504813A/ja active Pending
- 1997-10-17 AT AT97909451T patent/ATE284714T1/de active
- 1997-10-17 US US08/953,514 patent/US5977313A/en not_active Expired - Lifetime
- 1997-10-17 ES ES97909451T patent/ES2232862T3/es not_active Expired - Lifetime
- 1997-10-17 DE DE69731985T patent/DE69731985T2/de not_active Expired - Lifetime
- 1997-10-17 CA CA2269335A patent/CA2269335C/en not_active Expired - Fee Related
- 1997-10-20 AR ARP970104847A patent/AR008680A1/es unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039128A1 (en) * | 1995-06-06 | 1996-12-12 | Hemosphere, Inc. | Protein particles for therapeutic and diagnostic use |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005504745A (ja) * | 2001-07-20 | 2005-02-17 | シエーリング アクチエンゲゼルシヤフト | 大環状金属錯体及び生体分子との結合体の製造のためのその使用 |
JP2011520913A (ja) * | 2008-05-16 | 2011-07-21 | バイエル・ヘルスケア・エルエルシー | 標的化凝固因子およびそれを使用する方法 |
US9422362B2 (en) | 2008-05-16 | 2016-08-23 | Bayer Healthcare Llc | Targeted coagulation factors and method of using the same |
JP2017025065A (ja) * | 2008-05-16 | 2017-02-02 | バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC | 標的化凝固因子およびそれを使用する方法 |
US10035840B2 (en) | 2008-05-16 | 2018-07-31 | Bayer Healthcare Llc | Targeted coagulation factors and method of using the same |
Also Published As
Publication number | Publication date |
---|---|
WO1998017319A2 (en) | 1998-04-30 |
CA2269335A1 (en) | 1998-04-30 |
DE69731985D1 (de) | 2005-01-20 |
AU4713597A (en) | 1998-05-15 |
EP1028752B1 (en) | 2004-12-15 |
AU718956B2 (en) | 2000-05-04 |
CA2269335C (en) | 2010-05-25 |
EP1028752A2 (en) | 2000-08-23 |
DE69731985T2 (de) | 2005-12-29 |
ES2232862T3 (es) | 2005-06-01 |
ATE284714T1 (de) | 2005-01-15 |
AR008680A1 (es) | 2000-02-09 |
US5977313A (en) | 1999-11-02 |
WO1998017319A3 (en) | 1998-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001504813A (ja) | 代用血小板、及びそれらの製造に適した抱合法 | |
JP4350165B2 (ja) | 架橋した微細粒子、及びそれら粒子の治療薬用ビヒクルとしての使用 | |
US5955108A (en) | Cross-linked microparticles and their use as therapeutic vehicles | |
US5972707A (en) | Gene delivery system | |
ES2215207T3 (es) | Microparticulas de macromoleculas y metodos de produccion. | |
JPH07508004A (ja) | プロテイノイド担体並びにその製造方法および使用方法 | |
EP1919508B1 (en) | Artificial platelets | |
RU2503464C2 (ru) | Биогель | |
JP2000511169A (ja) | 微粒子および創傷治療におけるその用途 | |
US20070281031A1 (en) | Microparticles and methods for production thereof | |
JP2001523648A (ja) | 2種の活性剤を含むコンジュゲート | |
JPH09504790A (ja) | 化学的触媒作用および細胞受容体活性化のための生化学的活性物質 | |
MXPA99003677A (en) | Platelet substitutes and conjugation methods suitable for their preparation | |
Magee et al. | Effect of process variables on the in vitro degradation of protein microspheres | |
WO2000035487A1 (en) | Pharmaceutical conjugates comprising two active agents | |
CN1240364A (zh) | 血小板替代物和适于其制备的缀合方法 | |
US20040235719A1 (en) | Soluble protein-polymer systems for drug delivery | |
MXPA97004503A (en) | Steril powder of interlocked materials and its | |
WO2000029028A1 (en) | Pharmaceutical conjugates of glycoproteins and insoluble carriers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041014 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041014 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20061129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080527 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080827 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081006 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080922 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081127 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090609 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091009 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20091210 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100527 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130321 |